Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
Multiple Sclerosis
About this trial
This is an interventional prevention trial for Multiple Sclerosis focused on measuring demyelination, relapse rate, Pegylated interferon beta-1a, side effects, flu-like symptoms, injection site reactions, prednisone
Eligibility Criteria
Inclusion Criteria:
- diagnosed any form of MS (relapsing remitting, primary progressive, secondary progressive), any EDSS (expanded stability status scale) score
Exclusion Criteria:
- prior allergic reaction to interferon products, congestive heart failure, elevated liver enzymes
Sites / Locations
- Holy Name Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Current Plegridy Users
New Plegridy Users
Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.